A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer

Japanese Journal of Clinical Oncology

Volumn 43, Issue 6, 2013, Pages 636-640

  Kameda, Ryo ^a   Ando, Tomoko ^a   Kobayashi, Satoshi ^a   Ueno, Makoto ^a   Ohkawa, Shinichi ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Biliary tract cancer; Cisplatin; Gemcitabine

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; ANEMIA; ARTICLE; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAHEPATIC BILE DUCT; KIDNEY FUNCTION; MALE; METASTASIS; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE;

BILIARY TRACT CANCER; CISPLATIN; GEMCITABINE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84878667260     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt059     Document Type: Article

References (20)

1. Kayama T. Cancer Statistics in Japan 2011. Japan: Foundation for Promotion of Cancer Research 2011 (In Japanese).
2. Furuse J, Takada T, Miyazaki M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinoma. J Hepatobiliary Pancreat Surg 2008;15:55-62.
3. Okusaka T, Ishii H, Funakoshi A, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 2006;57:647-53.
4. Valle J, Wasan H, Palmer HD, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med 2010;362:1273-81.
5. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481-5.
6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
7. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer. A comparative multicentre study in Japan. Br J Cancer 2010;103:469-74.
8. Rauchwerger DR, Firby PS, Hedley DW, et al. Equilibrative nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000;60:6075-9.
9. Spratlin J, SR, Glubrecht D, Dabbagh L, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas Adenocarcinoma. Clin Cancer Res 2004;10:6956-61.
10. Sebastiani V, Ricci F, Rubio-Viqueira B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006;12:2492-7.
11. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Intl J Cancer 2007;120:1355-63.
12. Duxbury MS, Ito H, Zinner MJ, et al. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemotherapy to gemcitabine. Oncogene 2004;23:1539-48.
13. Sato J, Kimura T, Saito T, et al. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2011;18:700-11.
14. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22:72-9.
15. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995;31A:2335-40.
16. van Moorsel CJ, Pinedo HM, Veerman G. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981-90.
17. Sasaki T, Isayama H, Nakai Y, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012;30:708-13.
18. Lee S, Oh SY, Kim BG, et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009;32:348-52.
19. Pino MS, Milella M, Gelibter A, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009;76:254-61.
20. Sasaki T, Isayama H, Nakai Y, et al. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol 2013;71:973-9.